NeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in chronic kidney disease (CKD). The drug consists of recombinant human erythropoietin and targets the erythropoietin receptor, initiating the same pathway as native erythropoietin and triggering increased blood production in bone marrow (EMC, 2017). NeoRecormon is comparable to Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) in terms of its clinical profile, with similar safety, efficacy, and dosing.
Key Topics Covered:
NeoRecormon: Anemia in chronic kidney disease
List of Figures
Figure 1: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015-24
List of Tables
Table 1: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015-24
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vdgpqh/neorecormon?w=4